Stay updated on Nivolumab and Ipilimumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Ipilimumab in Melanoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A related-topic link for melanoma was added to the study’s resource links.
    Difference
    0.1%
    Check dated 2026-11-15T14:33:27.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The record now presents details for the completed CheckMate 915 melanoma trial, including its design, eligibility criteria, outcomes, and study locations, instead of an error page.
    Difference
    100%
    Check dated 2026-11-08T14:07:48.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:34:22.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a transition to using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) across NIH content.
    Difference
    1%
    Check dated 2026-10-25T15:20:39.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T20:40:08.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.0 to v3.7.1. The page still displays a 403 error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-11T20:24:07.000Z thumbnail image

Stay in the know with updates to Nivolumab and Ipilimumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.